Clinical Trial Update: Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

This Phase 2 safety and efficacy study evaluates nab-paclitaxel alone or in combination with CC-486 (azacitidine) or durvalumab in second/third-line treatment f…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CC-486 (azacitidine)
• Durvalumab (durvalumab)
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: Celgene | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: COMPLETED | Results posted: 2018-08-10